课题基金 / 基金详情

The role of KLF5 in GI epithelial homeostasis and disease

The role of KLF5 in GI epithelial homeostasis and disease
KLF5 在胃肠道上皮稳态和疾病中的作用
批准号:
7888558
负责人:
JONATHAN P KATZ
金额:
$33.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2012-06-30

项目摘要

项目成果

JONATHAN P KATZ的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):Kr <$ppel样因子5(KLF 5; IKLF; BTEB 2)是一种具有体外促增殖特性的锌指转录因子,在胃肠道上皮细胞(包括食管基底细胞)的增殖细胞中表达。这些细胞与细胞外基质(ECM)的相互作用对它们的功能至关重要,我们已经证明Klf 5通过表皮生长因子受体(EGFR)调节食管上皮细胞的增殖。在新的初步数据中,我们证明Klf 5通过培养的原代食管角质形成细胞中的整合素连接激酶(ILK)增加迁移。鉴于这些发现,Klf 5是体内协调食管上皮细胞增殖和迁移的优秀候选者。然而,尽管有大量证据表明KLF 5在非转化上皮细胞中具有促增殖作用,但KLF 5抑制增殖,促进失巢凋亡,并减少食管鳞状细胞癌细胞的侵袭。KLF 5也在人类乳腺癌和前列腺癌以及小鼠和人类的肠腺瘤中缺失或下调。在上皮癌细胞中,KLF 5蛋白比在非转化上皮细胞中经历更快的降解。这些发现表明,KLF 5功能的消失可能是重要的致癌作用。事实上,KLF 5已被认为在人类乳腺癌、前列腺癌、食管癌和结肠癌中具有肿瘤抑制功能。KLF 5的这种二分作用并不是唯一的,因为已经报道了其他因子的不同功能,如TGF?,Notch和KLF 4。在这里,我们将通过检验以下假设来研究KLF 5在正常和转化食管中的作用:(1)KLF 5是食管中的转运放大细胞的增殖、分化和迁移的关键调节因子;(2)KLF 5的缺失是食管恶性转化的关键步骤。我们将通过以下相互关联的具体目标来检验这些假设。在具体目标1中,我们将通过以下方式研究KLF 5在食管上皮稳态中的作用:(a)评价KLF 5过表达或抑制的非转化角质形成细胞中的整合素、整合素相关激酶(ILK)和表皮生长因子受体(EGFR)信号传导;(B)研究KLF 5对EGFR和ILK的转录调控;(c)检查食管中KLF 5转基因表达的小鼠。在具体目标2中,我们将通过以下方式确定KLF 5在食管肿瘤发生中的功能:(a)检查KLF 5在转化的食管鳞状细胞中对整合素、ILK和EGFR通路的调节;和(B)评估食管中Klf 5转基因表达的小鼠中的发育异常和肿瘤形成,所述小鼠已经用致癌物NMBA处理或与ED-L2/细胞周期蛋白D1转基因小鼠杂交,一个已建立的遗传癌症模型。总之,了解KLF 5在食管上皮中调控的途径将为了解食管疾病(良性和恶性)的分子事件提供一个框架。公共卫生相关性:食管疾病,如胃食管反流病和食管癌,是美国和全世界最常见的疾病之一,这些疾病是由正常上皮稳态失调引起的。因此,赞赏的分子机制,包括特定的因素和复杂的信号阵列,管理正常的食管增殖和分化是至关重要的食管疾病,良性和恶性的理解。本申请中提出的研究旨在通过对关键调节蛋白KLF 5的研究来阐明这些因子和信号通路。
英文摘要
DESCRIPTION (provided by applicant): Kr¿ppel-like factor 5 (KLF5; IKLF; BTEB2), a zinc-finger transcription factor with pro-proliferative properties in vitro, is expressed in proliferating cells of gastrointestinal tract epithelia, including the basal cells of the esophagus. The interplay of these cells with the extracellular matrix (ECM) is critical to their function, and we have shown that Klf5 regulates proliferation in esophageal epithelial cells through the epidermal growth factor receptor (EGFR). In novel preliminary data, we demonstrate that Klf5 increases migration via the integrin- linked kinase (ILK) in primary esophageal keratinocytes in culture. Given these findings, Klf5 is an excellent candidate to orchestrate esophageal epithelial cell proliferation and migration in vivo. However, despite significant evidence of a pro-proliferative role for KLF5 in non-transformed epithelial cells, KLF5 inhibits proliferation, promotes anoikis, and decreases invasion of esophageal squamous cancer cells. KLF5 is also deleted or down-regulated in human breast and prostate cancers, as well as intestinal adenomas from mice and humans. In epithelial cancer cells, KLF5 protein undergoes more rapid degradation than in non- transformed epithelial cells. These findings suggest that extinction of KLF5 function may be important for carcinogenesis. In fact, KLF5 has been suggested to have tumor suppressive functions in human breast, prostate, esophageal, and colon cancers. This dichotomous role for KLF5 is not unique, as divergent functions have been reported for other factors, such as TGF?, Notch, and KLF4. Here, we will investigate the role of KLF5 in normal and transformed esophagus by testing the following hypotheses: (1) KLF5 is a critical regulator of proliferation, differentiation, and migration in transit amplifying cells of the esophagus; and (2) loss of KLF5 is a key step in malignant transformation in the esophagus. We will test these hypotheses through the following interrelated Specific Aims. In Specific Aim 1, we will investigate the role of KLF5 in esophageal epithelial homeostasis by: (a) evaluating integrin, integrin-linked kinase (ILK), and epidermal growth factor receptor (EGFR) signaling in non-transformed keratinocytes with overexpression or suppression of KLF5; (b) studying the transcriptional regulation of EGFR and ILK by KLF5; (c) examining mice with transgenic expression of Klf5 in the esophagus. In Specific Aim 2, we will determine the function of KLF5 during esophageal tumorigenesis by: (a) examining the regulation of the integrin, ILK, and EGFR pathways by KLF5 in transformed esophageal squamous cells; and (b) evaluating dysplasia and tumor formation in mice with transgenic expression of Klf5 in esophagus which have been treated with the carcinogen NMBA or crossed with ED-L2/cyclin D1 transgenic mice, an established genetic cancer model. Overall, an understanding of the pathways regulated by KLF5 in esophageal epithelia will provide a framework to understand the molecular events underlying esophageal diseases, both benign and malignant. PUBLIC HEALTH RELEVANCE: Diseases of the esophagus, such as gastroesophageal reflux disease and esophageal cancer, are among the most common ailments in the United States and throughout the world, and these diseases result from dysregulation of normal epithelial homeostasis. Thus, an appreciation of the molecular mechanisms, including the specific factors and complex signaling arrays, which govern normal esophageal proliferation and differentiation is critical to the understanding of esophageal diseases, both benign and malignant. The research proposed in this application aims to elucidate these factors and signaling pathways through studies of the key regulatory protein KLF5.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cytoprotective pathways in esophageal squamous epithelia
  • 批准号:
    10660394
  • 项目类别:
  • 资助金额:
    $59.66万
  • 财政年份:
    2023
  • 负责人:
    JONATHAN P KATZ
  • 依托单位:
Molecular Pathology and Imaging Core
  • 批准号:
    9762894
  • 项目类别:
  • 资助金额:
    $16.56万
  • 财政年份:
    2019
  • 负责人:
    JONATHAN P KATZ
  • 依托单位:
KLF4 and WNT5A in esophageal epithelial differentiation and stratification
  • 批准号:
    9889959
  • 项目类别:
  • 资助金额:
    $36.45万
  • 财政年份:
    2019
  • 负责人:
    JONATHAN P KATZ
  • 依托单位:
KLF4 and WNT5A in esophageal epithelial differentiation and stratification
  • 批准号:
    10374840
  • 项目类别:
  • 资助金额:
    $36.56万
  • 财政年份:
    2019
  • 负责人:
    JONATHAN P KATZ
  • 依托单位:
国内基金
海外基金
胃肠安方抑制整合素αvβ6促进胃癌细胞Anoikis防治胃癌转移的机制研究
  • 批准号:
    82305335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    卢艳琳
  • 依托单位:
AMPK通路调控CEMIP诱导自噬对前列腺癌细胞anoikis耐受的影响及机制
  • 批准号:
    81772751
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2017
  • 负责人:
    邢毅飞
  • 依托单位:
Myxoma 病毒蛋白Serp-1促进肝癌细胞Anoikis的作用及机制研究
  • 批准号:
    81372597
  • 项目类别:
    面上项目
  • 资助金额:
    16.0万元
  • 批准年份:
    2013
  • 负责人:
    陈昊
  • 依托单位:
TrkB/BDNF通路对前列腺癌EMT、anoikis和血管生成的影响及分子机制
  • 批准号:
    81272847
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2012
  • 负责人:
    邢毅飞
  • 依托单位: